Lions Gate Entertainment Corp. (USA) (LGF) Bears Rejoice on Earnings Miss

The odds were not in Lions Gate Entertainment Corp.'s (USA) (LGF) favor

by Josh Selway

Published on Feb 5, 2016 at 3:19 PM

Lions Gate Entertainment Corp. (USA) (NYSE:LGF) hit a three-year low earlier of $16.21, and was last seen off 34.7% at $16.61, after the company reported lackluster quarterly results, citing weakness from its "The Hunger Games: Mockingjay Part 2" movie as the key reason. Despite the pain shareholders may be feeling, this price action benefits at least two groups of traders. 

For one, option speculators had been targeting puts at a breakneck pace leading up to the quarterly event. To be more specific, LGF's 10-day put/call volume ratio of 1.30 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in just 10 percentage points shy of an annual high. In short, put buying has been unusually popular of late, compared to call buying. 

Elsewhere, the stock is also a favorite among short sellers. Over 11% of LGF's float is controlled by shorts, and at the stock's average daily volumes, it would take them nearly seven sessions to buy back their shares. 

There is at least one group of bullish holdouts, however. Ninety-one percent of analysts that cover Lions Gate Entertainment Corp. (USA) (NYSE:LGF) say it's a "buy" or better, while none say it's a "sell." And even during today's dramatic sell-off, the only negative note came from Stifel, which cut its price target to $35 from $42.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Legendary Stock-Picker Calls Top Stock of 2020
Matt McCall's picks were met with disbelief... Until five soared over 1,000%. Get his latest 2020 pick.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.